152 related articles for article (PubMed ID: 37890416)
1. TERT promoter mutations and gene amplification in endometrial cancer.
Praiss AM; Marra A; Zhou Q; Rios-Doria E; Momeni-Boroujeni A; Iasonos A; Selenica P; Brown DN; Aghajanian C; Abu-Rustum NR; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Dec; 179():16-23. PubMed ID: 37890416
[TBL] [Abstract][Full Text] [Related]
2. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Da Cruz Paula A; DeLair DF; Ferrando L; Fix DJ; Soslow RA; Park KJ; Chiang S; Reis-Filho JS; Zehir A; Donoghue MTA; Wu M; Brown DN; Murali R; Friedman CF; Zamarin D; Makker V; Mueller JJ; Leitao MM; Abu-Rustum NR; Aghajanian C; Weigelt B
Gynecol Oncol; 2021 May; 161(2):535-544. PubMed ID: 33622519
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and Genomic Analysis of
Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
6. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
Ross DS; Devereaux KA; Jin C; Lin DY; Zhang Y; Marra A; Makker V; Weigelt B; Ellenson LH; Chui MH
Mod Pathol; 2022 Jul; 35(7):962-971. PubMed ID: 34972830
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
[TBL] [Abstract][Full Text] [Related]
9. High-resolution copy number analysis of clear cell endometrial carcinoma.
O'Hara AJ; Le Gallo M; Rudd ML; Bell DW
Cancer Genet; 2020 Jan; 240():5-14. PubMed ID: 31678638
[TBL] [Abstract][Full Text] [Related]
10. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
[TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile.
Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
Front Oncol; 2023; 13():1105504. PubMed ID: 37287928
[TBL] [Abstract][Full Text] [Related]
12. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
13. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
da Silva EM; Selenica P; Vahdatinia M; Pareja F; Da Cruz Paula A; Ferrando L; Gazzo AM; Dopeso H; Ross DS; Bakhteri A; Riaz N; Chandarlapaty S; Razavi P; Norton L; Wen HY; Brogi E; Weigelt B; Zhang H; Reis-Filho JS
NPJ Breast Cancer; 2021 Apr; 7(1):43. PubMed ID: 33863915
[TBL] [Abstract][Full Text] [Related]
16. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
17. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
18. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Whelan K; Dillon M; Strickland KC; Pothuri B; Bae-Jump V; Borden LE; Thaker PH; Haight P; Arend RC; Ko E; Jackson AL; Corr BR; Ayoola-Adeola M; Wright JD; Podwika S; Smitherman C; Thomas S; Lightfoot M; Newton M; Washington C; Mullen M; Cosgrove C; Harsono AAH; Powell K; Herzog TJ; Salani R; Alvarez Secord A
Gynecol Oncol; 2023 Nov; 178():44-53. PubMed ID: 37748270
[TBL] [Abstract][Full Text] [Related]
19. Genomic landscape of endometrial carcinomas of no specific molecular profile.
Momeni-Boroujeni A; Nguyen B; Vanderbilt CM; Ladanyi M; Abu-Rustum NR; Aghajanian C; Ellenson LH; Weigelt B; Soslow RA
Mod Pathol; 2022 Sep; 35(9):1269-1278. PubMed ID: 35365770
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations and prognosis in solitary fibrous tumor.
Bahrami A; Lee S; Schaefer IM; Boland JM; Patton KT; Pounds S; Fletcher CD
Mod Pathol; 2016 Dec; 29(12):1511-1522. PubMed ID: 27562490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
